The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man
We characterized the world's second case with ascertained extreme resilience to autosomal
dominant Alzheimer's disease (ADAD). Side-by-side comparisons of this male case and the …
dominant Alzheimer's disease (ADAD). Side-by-side comparisons of this male case and the …
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …
understanding of the timing of disease-related changes in tau. We quantified the …
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ …
In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
R van der Kant, LSB Goldstein… - Nature Reviews …, 2020 - nature.com
The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …
can revert or arrest progression of this disease. AD pathology is characterized by the …
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …
Imaging the evolution and pathophysiology of Alzheimer disease
W Jagust - Nature Reviews Neuroscience, 2018 - nature.com
Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …
studies of the relationships between the two major proteins deposited in this disease …
Dissecting the clinical heterogeneity of early-onset Alzheimer's disease
Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …